Aviance Capital Partners LLC Increases Stake in Novo Nordisk A/S (NYSE:NVO)

Aviance Capital Partners LLC boosted its position in Novo Nordisk A/S (NYSE:NVO) by 4.7% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 17,091 shares of the company’s stock after acquiring an additional 770 shares during the period. Aviance Capital Partners LLC’s holdings in Novo Nordisk A/S were worth $2,035,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Natixis Advisors LLC lifted its stake in shares of Novo Nordisk A/S by 2.7% during the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after buying an additional 80,070 shares in the last quarter. Zions Bancorporation N.A. raised its holdings in Novo Nordisk A/S by 57.0% during the 3rd quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock valued at $2,207,000 after acquiring an additional 6,726 shares during the period. Wealth Enhancement Advisory Services LLC lifted its position in shares of Novo Nordisk A/S by 14.8% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock worth $34,463,000 after acquiring an additional 37,346 shares in the last quarter. Private Wealth Partners LLC boosted its holdings in shares of Novo Nordisk A/S by 155.1% in the third quarter. Private Wealth Partners LLC now owns 33,203 shares of the company’s stock worth $3,953,000 after acquiring an additional 20,188 shares during the period. Finally, Buckingham Capital Management Inc. bought a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at $3,874,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Down 1.9 %

Shares of NYSE NVO opened at $99.82 on Tuesday. The stock has a market capitalization of $447.95 billion, a P/E ratio of 32.30, a PEG ratio of 1.31 and a beta of 0.42. Novo Nordisk A/S has a one year low of $94.73 and a one year high of $148.15. The firm’s 50 day simple moving average is $117.94 and its two-hundred day simple moving average is $129.42. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75.

Analyst Upgrades and Downgrades

Several research analysts have commented on NVO shares. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. BMO Capital Markets cut their price target on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Buy” and an average price target of $144.50.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.